

SCIENTIFIC ARTICLES/ CLINICAL STUDIES

Sodium Phenylbutyrate & Sodium Phenylacetate

4-Phenylbutyric Acid, Sodium Salt - Phenylacetic Acid, Sodium Salt

CANCER

- Holm, E; Schade, I. Effects of short-chain and saturated long-chain fatty acids on tumor growth-in vitro and experimental in vivo effects. *Aktuelle Ernährungsmedizin* 2008;33(5):225-230.
- Cortez, CC; Jones, PA. Chromatin, cancer and drug therapies. *Mutat Res-Fundam Mol Mech Mutagen* 2008;647(1-2):44-51.
- Murahari, S; Jalkanen, AL; Kulp, SK; Chen, C-S; Jubala, CM; Fosmire, SP; Modiano, JF; Fossey, SL; London, CA, Kisseberth, WC.OSU-HDAC42, a novel histone deacetylase inhibitor with potent antitumor effects on human and canine osteosarcoma cells. *Proceedings of the American Association for Cancer Research Annual Meeting* 2008;49:578.
- Wang, C., Meng, M., Zhang, J., Jin, C., Jiang, J., Ren, H., Jiang, J., Qin, C., and Yu, D. *Chinese Medical Journal* 2008; 121(17):1707-1711.
- Burkitt, Kyunghee and Ljungman, Mats. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. *Molecular Cancer* 7:24, March 2008.
- Svechnikova, Irina, Almqvist, Per M., Ekström, Tomas J. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. *International Journal of Oncology* 32:821-827, 2008
- Huynh, L; Grant, J; Leroux, JC; Delmas, P; Allen, C. Prediction the solubility of the anti-cancer agent docetaxel in small molecule excipients using computational methods. *Pharm Res* 2008; 25:147-157.
- Hurtubise, A; Bernstein, ML; Momparler, RL. Preclinical evaluation of the antineoplastic action of 5-aza-2'-deoxycytidine and different histone deacetylase inhibitors on human Ewing's sarcoma cells. *Cancer Cell Int* 2008;8:16.
- Koutsourea, AI; Fousteris, MA; Arsenou, ES; Papageorgiou, A; Pairas, GN; Nikolaropoulos, SS. Rational design, synthesis and in vivo evaluation of the antileukemic activity of six new alkylating steroidal esters. *Bioorg Med Chem* 2008;16(9):5207-5215.

- Estey, E. New drugs in acute myeloid leukemia. *Seminars in Oncology* 2008;35(4):439-448.
- Picard, V; Bergeron, A.; Larue, H; Fradet, Y. MAGE-A9 mRNA and protein expression in bladder cancer. *Int J Cancer* 2007; 120 (10):2170-2177.
- Vila-Carriles, WH; Zhou, Z-H; Bubiën, JK; Fuller, CM; Benos, DJ. Participation of the chaperone Hsc70 in the trafficking and functional expression of ASIC2 in glioma cells. *J Biol Chem* 2007;282(47):34381-34391.
- Entin-Meer, M; Rephaeli, A; Yang, X; Nudelman, A; Haas-Kogan, DA. AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. *Cancer Lett* 2007; 253(2):205-214.
- Christov, Konstantin, Grubbs, Clinton J; Shilkaitis, Anne, Juliana, M Margaret; Lubet, Ronald A. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model. *Clin Cancer Res* 2007; 13(18 Part. 1):5488-5496.
- Christov, K; Grubbs, C; Juliana, M; Luber, R. Correlation of the preventive/therapeutic efficacy of agents in the methylnitrosourea (MNU) mammary cancer model with changes in cell proliferation and apoptosis following short-term treatment. *Proceedings of the American Association for Cancer Research Annual Meeting* 2007; 48:997.
- Sung, MW; Waxman, S. Combination of cytotoxic-differentiation therapy with 5-fluorouracil and phenylbutyrate in patients with advanced colorectal cancer. *Anticancer Res* 2007;27(2):995-1001.
- Caraway, HE; Gore, SD. Addition of histone deacetylase inhibitors in combination therapy. *J. Clin Oncol* 2007; 25(15):1955-1956.
- Verheul, HMW; Qian, DZ; Carducci, MA; Pili, R. Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. *Cancer Chemother Pharmacol* 2007; 60(3):329-339.
- Ammerpohl, O; Trauzold, A; Schniewind, B; Griep, U; Pilarsky, C; Grutzmann, R; Saeger, H-D; Janssen, O; Sipos, B; Kloppel, G; Kalthoff, H. Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells. *Br J Cancer* 2007; 96(1):73-81.
- Jiemjit, A; Fandy, TE; Baylin, SB; Carraway, H; Herman, JG; Gore, SD. Sequential administration of DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi) induces apoptosis with caspase and reactive oxygen species (ROS)-dependent synergy. *Proceedings of the American Association for Cancer Research Annual Meeting* 2007; 48:249.
- Hattori, Y; Fukushima, M; Maitani, Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. *Int J Oncol* 2007;30(6):1427-1439.
- Lyon, CM; Klinge, D; Liechty, KC; Grimes, MJ; Grimes, J; Thomas, C; March, T; Stidley, C; Keith, R; Belinsky, SA. Rosiglitazone prevents the progression of pre-invasive lung cancer in a murine model. *Proceedings of the American Association for Cancer Research Annual Meeting* 2007; 48:395.
- Cunha De Santis, G; de Barros Tamarozzi, M; Sousa, RB; Moreno, S; Secco, D; Garcia, AB; Lima, ASG; Faccioli, LH; Falcao, RP; Cunha, FQ; Rego, EM. Adhesion molecules and Differentiation Syndrome: phenotypic and functional analysis of the effect of ATRA, As203, phenylbutyrate, and G-CSF in acute promyelocytic leukemia. *Haematologica* 2007; 92(12):1615-1622.

- Meng, M; Wang, C-T; Jiang, J-M; Zhang, J-C; Jiang, J-J; Jin, C-J. Expression of histone deacetylase 4 in human liver carcinoma cell line Bel-7402 and its significance. *Chinese Journal of Cancer Biotherapy Chin. J. cancer Biother* 2007; 14(2):153-157.
- Lu, Y-S; Kashida, Y; Kulp, SK; wang, Y-C; Wang, D; Hung, J-H; Tang, M; Lin, Z-Z; Chen, T-J; Cheng, A-L; Chen, C-S. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. *Hepatology* 2007; 46(4):1119-1130.
- Svechnikova, I; Ammerpohl, O; Ekstroem, TJ. p21waf1/Cip1 partially mediates apoptosis in hepatocellular carcinoma cells. *Biochem Biophys Res Commun* 2007; 354(2):466-471.
- Lu, Y-S; Kashida, Y; Jung, J-H; Chen, C-S; Wang, Y-C; Cheng, A-L; Chen, C-S. In vivo efficacy of OSH-HDAC42, a novel phenylbutyrate-based histone deacetylase inhibitor, in human hepatocellular carcinoma animal models. *Proceedings of the American Association for Cancer Research Annual Meeting* 2007; 48:169.
- Lubbert, M; Claus, R. Epigenetic inactivation of gene expression. New therapeutic targets in hematology. *Onkologie* 2007;13(1):46-55.
- Claus, R; Router, B, Lubberrt, M. Targets of epigenetics therapy-Gene reactivation as a novel approach in MDS treatment. *Cancer Treat Rec* 2007; 33(Suppl. 1):S47-S52.
- Luebbert, M. Which myelodysplastic syndromes patients are candidates for treatment with decitabine. *Leukemia Research* 2007; 31(Suppl. 1):S20.
- Gore, SD. Do histone deacetylase inhibitors have a place in the treatment of myelodysplastic syndromes? *Leukemia Research* 2007; 31(Suppl. 1):S21.
- Phillips, JA; Griffin, BE. Pilot study of sodium phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. *Trans R Soc Trop Med Hyg* 2007; 101(12):1265-1269.
- Milkevitch, M; Jeitner, TM; Beardsley, NJ; Delikatny, EJ. Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells. *Biochim Biophys Acta* 2007; 1771(9):1166-1176.
- Phillips John A., Griffin, Beverly E. Pilot study of sodium Phenylbutyrate as adjuvant in cyclophosphamide-resistant endemic Burkitt's lymphoma. *Royal Society of Tropical Medicine and Hygiene* doi:10.1016/j.trstmh.2007.06.0200.
- Lopez, CA, Feng, FY, Herman, JM, Nyati, MK, Lawrence, TS, Ljungman, M. Phenylbutyrate Sensitizes Human Glioblastoma Cells Lacking Wild-Type P53 Function To Ionizing Radiation. *Int. J. Radiation Oncology Biol. Phys.*, Vol. 69, No. 1, PP. 214-220, 2007.
- L.H. Camacho, J. Olson, W.P. Tong, W. Young, D.R. Spriggs, M.G. Malkin. Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. *Invest. New Drugs*, 2007 25:131-138.
- Vila-Carriles, WH; Kovacs, GG; Bubien, JK; Gillespie GY; Fuller, CM; Benos, DJ. Cellular localization of acid sensing ion channels in human astrocytes and gliomas. *FASEB Journal* 2006; 20(4, Part1):A325.
- Christov, K; Grubbs, C; Lubet, R; Altered cell proliferation and apoptosis as biomarkers for identifying preventive/therapeutic agents against chemically induced mammary cancers. *Breast Cancer Research and Treatment* 2006; 100(Suppl. 1):S58.

- Lea, MA; Ibeh, C; Shah, N; Moyer, MP. Enhanced differentiation of colon cancer cells induced by combinations of inhibitors of kinases and of histone deacetylases. Proceedings of the American Association for Cancer Research Annual Meeting 2006; 47:1184.
- Gore, SD; Jiemjit, A; Silverman, LB; Aucott, T; Baylin, S; Carraway, H; Douses, T; Fandy, T; Herman, J; Karp, JE; Licht, JD.; Murgo, AJ.; Odchimar-Reissig, R; Smith, BD; Zwiebel, JA.; Sugar, E. Combined methyltransferase/Histone deacetylase inhibition with 5Azacitidine and MS-275 in patients with MDS, CMMoL and AML: Clinical response, Histone Acetylation and DNA damage. Blood 2006; 108(11, part 1):156A-157A.
- Sun, J; Liu, S; Yu, J; Wei, M; Mao, C; Ding, H; Kearney, J; Huynh, L; Paschka, P; Wang, D; Klisovic, RB; Perrotti, D; Chen, C-S; Blum, WG; Marcucci, G. Characterization of HDAC1 OSU42 as a novel histone deacetylase inhibitor in AML cell lines. Blood 2006; 108(11 Part 1):563A.
- Gore, SD; Baylin, S; Sugar, E; Carraway, H; Miller, CB; Carducci, M; Grever, M; Galm, O; Douses, T; Karp, JE; Rudek, MA; Zhao, M; Smith, BD; Manning, J; Jiemjit, A; Dover, G; Mays, A; Zwiebel, J; Murgo, A; Weng, L-J; Herman, JG. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66(12):6361-6369.
- Brock, MV. Clinical aspects of molecular biology for the diagnosis and treatment of esophageal cancer. Esophagus 2006; 3(3):91-94.
- Beyer, SJ; Kulp, SK; Baird, M; Auer, H; Kornacker, K; Chen, C-S; Beer, DG; Kresty, LA. The effects of a phenylbutyrate-driven histone deacetylase inhibitor (HDAC-42) on acid-induced gene expression patterns of SEG-1 human esophageal adenocarcinoma cells. Proceedings of the American Association for Cancer Research Annual Meeting 2006; 47:1128-1129.
- West, DA; Lucas, DM; Davis, ME; De lay, MD; Johnson, AJ; Guster, SE; Freitas, MA; Parthun, MR; Wang, D; Kulp, SK; Grever, MR; Chen, C-S; Byrd, JC. The novel histone deacetylase inhibitor OSU-HDAC42 has class I and II histone deacetylase (HDAC) inhibitory activity and represents a novel therapy for chronic lymphocytic leukemia. Blood 2006; 108(11 Part 1): 794A-795A.
- Lyon, CM; Klinge, D; Liechty, KC; Belinsky, SA. DNA demethylating agents and a PPA-gamma agonist cooperate to induce apoptosis in lung cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 2006; 47:10.
- Meletis, J; Viniou, N; Terpos, E. Novel agents for the management of myelodysplastic syndromes. Med Sci Monit 2006; 12(9):RA 194-RA206.
- Kulp, SK; Chen, C-S; Wang, D-S; Chen, C-Y; Chen, C-S. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer. Clin Cancer Res 2006; 12(17):5199-5206.
- Wanda H. Vila-Carriles, Gergely Gy Kovacs, Biljana Jovov, Zhen-Hong Zhou, Amit K. Pahwa, Garrett Colby, Ogenna Esimai, G. Yancey Gillespie, Timothy B. Mapstone, James M. Markert, Catherine M. Fuller, James K. Buben, Dale J. Benos. Surface Expression of ASIC2 Inhibits the Amiloride-sensitive Current and Migration of Glioma Cells. *The Journal of Biological Chemistry* VOL. 281, NO> 28, pp. 19220 – 19232, July 14, 2006.
- Mack, GS. Epigenetic cancer therapy makes headway. Journal of the National Cancer Institute 2006;98(20):1443-1444.
- Fouladi, M. Histone deacetylase inhibitors in cancer therapy. Cancer Investigation 2006;24(5):521-527.
- Galm, O; Herman, JG; Baylin, SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006;20(1):1-13.

- P. Malask, S. Chanel, L.H. Camacho, S. Soignet, P.O. Dandolfi, I. Guernah, R. Warrell, S. Nimer. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. *Leukemia* 2006, 20, 212-217.
- Schniewind B., Heintz K., Kurdow R., Ammerpohl O., Trauzold A., Emme D., Dohrmann P., Kalthoff H. Combination Phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathways. *Journal of Carcinogenesis* 2006,1477-3163-5-25.
- Jin C., Park J.W., Choi J.W., Kang H., Jin G.B., Choi S.M., Park S.S., Ryu D., Jang L.C. Antiproliferative Effect of Phenylbutyrate in AsPC-1 Pancreatic Cancer Cell Line. *Korean J. Hepatobiliary Pancreat Surg.* 2006 Mar: 10(1):1-9. Korean
- Kouraklis G., Theocharis S. Histone deacetylase inhibitors: A novel target of anticancer therapy (Review). *Oncology Reports* 15: 489-494, 2006.
- Sampathkumar S-g, Jones MB, Meledeo MA, Hida K, Sheh T, Gomatputra P, Yarema KJ. Carbohydrate-based small molecules as anti-cancer drugs: Short chain fatty acid-hexosamine hybrids. *Glycobiology* 2005; 15 (11): 1249-1250.
- Lu Q, Wang D-S, Chenm C-S, Hu Y-D, Chen C-S. Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors. *J Med Chem* 2005; 48 (17): 5530-5535.
- Gao, J; X-y; Xu F-l; Liu D-y; Lei D-p. Effects of sodium phenylbutyrate alone or in combination with fluorouracil or cisplatin on laryngeal carcinoma Hep-2 cell line. *Zhongguo Xinyao yu Linchuang Zazhi* 2005; 24(10):778-781.
- Gao, J; Ruan, X; Pan, X; Xu, F; Lei, D; Liu, D. The effect of sodium phenylbutyrate to agents used in induction chemotherapy on laryngeal carcinoma cells Hep-2 in vitro. *Lin Chuang Er Bi Yan Hou Ke Za Zhi* 2005; 19(15):680-682.
- Luebbert, M. Combined targeting of the epigenetic silence in leukemia: Cooperating activities of DNA methylation and histone deacetylation inhibitors. *Leukemia Research* 2005; 29(7):727-728.
- Wang, H-E; Wu, H-C; Kao, S-J; Tseng, F-W; Wang, Y-S; Yu, H-M; Chou, S-L; Yen, S-H; Chi, K-H. Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell. *Biochem Pharmacol* 2005; 69(4):617-626.
- Milkevitch, M; Shim, H; Pilatus, U; Pickup, S; Wehrle, JP; Samid, D; Poptani, H; Glickson, JD; Delikatny, EJ. Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. *Biochim Biophys Acta* 2005; 1734(1):1-12.
- Rudek MA, Zhao M, He P, Hartkle C, Gilbert J, Gore SD,. Carducci MA, Baker SD. Pharmacokinetics of 5-Azacytidine Administered With Phenylbutyrate in Patients With Refractory Solid Tumors or Hematologic Malignancies. *Journal of Clinical Oncology* Vol 23 #17 June 10, 2005.
- Belinsky S.A., Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. *Carcinogenesis* Vol. 26, No. 9 (1481-1487) 2005.

- Mortazavi, A.; Hoot, DR; Carlton, PS; Wang, S; Degroff, VL.; Lu, Q; Kulp, S; Chen, C-S; Clinton, SK. Inhibition of cell growth and induction of apoptosis in bladder cancer cell lines by a novel histone deacetylase inhibitor derived from phenylbutyrate. *Proceedings of the American Association for Cancer Research Annual meeting 2005*; 46(Supplement S): 422.
- Hao, C-l; Tang, K-j; Chen, S, Xing, H-y; Wang, M; Wang, J-x. 5-Aza-2'-deoxycytidine enhances differentiation and apoptosis induced by phenylbutyrate in Kasumi-1 cells. *Zhonghua Zhong Liu Za Zhi* 2005;27(3):148-151.
- Meng M., Jiang J.M., Liu H., In C.Y., Zhu J.R. Effects of sodium phenylbutyrate on differentiation and induction of the P²¹^{WAF1/CIP1} anti-oncogene in human liver carcinoma cells lines. *Chinese Journal of Digestive Diseases* 2005; 6; 189-192.
- Garcia-Manero, G; Issa, J-P. Histone deacetylase inhibitors: A review of their clinical status as antineoplastic agents. *Cancer Investigation* 2005;23(7):635-642.
- Monneret, C. Histone deacetylase inhibitors. *Eur J Med Chem* 2005;40(1):1-13.
- Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, Fisher JD, Carducci MA. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study. *Neuro-Oncology* Vol 7 pg 177-182, April 2005.
- Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs MI, Tucker SL, Ismail S, Stevens C, Meyn RE. Histone deacetylase inhibitors radiosensitize human melanoma cell by suppressing DNA repair activity. *Clin Cancer Res* 2005; 11 (13): 4912-4922.
- Siitonen, T., Koistinen, P., Savolainen, E. Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27^{Kip1} in acute myeloblastic leukemia cells. *Leukemia Research* 29 (2004) 1335-1342.
- Liu M., Brusilow W.S.A., Needleman R., Activity of the yeast Tat2p tryptophan permease is sensitive to the anti-tumor agent 4-phenylbutyrate. *Curr Genet* 46:256-268 (2004).
- Emionite L., Galmozzi F., Grattarola M., Boccardo F., Vergani L, Toma S., Histone Deacetylase Inhibitors Enhance Retinoid Response in Human Breast Cancer Cell Lines. *Anticancer Research* 24: 4019-4024 (2004).
- Zhang X., Wei L., Yang Y., Yu Q. Sodium 4-Phenylbutyrate Induces Apoptosis of Human Lung Carcinoma Cells Through Activating JNK Pathway. *Journal of Cellular Biochemistry* 93:819-829 (2004).
- Sachs M.D., Ramamurthy M., van der Poel H., Wickham T.J., Lamfers M., Gerritsen W., Chowdhury W., Li Y., Schoenberg M.P., Rodriguez R. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. *Cancer Gene Therapy* (2004) 11, 477-486.
- Nakagawa H., Intrathecal or intracavitary administration of sodium butyrate to treat neoplastic meningitis and malignant glioma *Proceedings of the AACR*, Vol. 45:5241, March 2004.
- X.-N. Li, S. Parikh, Q. Shu, H.-L. Jung, C.-W. Chow, L. Perlaky, H.-C. E. Leung, J. Su, S. Blaney, and C. C. Lau Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells *Clin. Cancer Res.*, February 1, 2004; 10(3): 1150 - 1159.

- Burzynski, SR, Lewy, RI, Weaver, R, Janicki, T, Jurida, G, Khan, M, Larisma, CB, Paszkowiak, J, , Szymkowski, B. Long-Term Survival and Complete Response of a Patient With Recurrent Diffuse Intrinsic Brain Ctem Glioblastoma Multiforme. *Integrative Cancer Therapies*, 3(3); 2004 pp. 257-261.
- Appelskog I.B., Ammerpohl O., Svechnikova I.G., Lui W-O., Almqvist P.M., Ekström T.J. Histone deacetylase inhibitor 4-phenylbutyrate suppresses GAPDH mRNA expression in glioma cells. *International Journal of Oncology* 24:1419-1425, 2004.
- Linz, Uta, Complete response of a recurrent, multicentric malignant glioma in a patient treated with Phenylbutyrate. *Journal of Neuro-Oncology* 66:251, 2004.
- Asklune, T., Appelskog I.B., Ammerpohl O., Ekstron T.J., Almqvist, P.M. Histone deacetylase inhibitor 4-phenylbutyrate modulates glial fibrillary acidic protein and connexin 43 expression, and enhances gap-junction communication in human glioblastoma cells. *European Journal of Cancer*, 2004 Vol 40, No. 7.
- Gray S.G., Quian C.-N., Furge K., Guo X., The B.T., Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. *Int. J of Onc.* 24:773-795, 2004.
- Chung, Yih-Lin, Wang, Ae-June, Yao, Lin-Fen, Antitumor Histone deacetylase inhibitors suppress cutaneous radiation syndrome: Implications for increasing therapeutic gain in cancer radiotherapy. *Molecular Cancer Therapeutics* 2004; 3(3):317-325
- Belinsky S.A., Klinge D.M., Stidley C.A., Issa J-P., Herman J.G., March T.H., Baylin S.B., Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer. *Cancer Research* (63) 7089-7093, November 1, 2003.
- Sun Li-Jun, Huang Qiang, Lan Qing, Du Zi-wei, Hu Geng-xi, Wang Ai-dong, Gene Expression Profiling of Phenylbutyrate Induced Differentiation of Glioma Cells by cDNA Array. *Chinese Journal of Cancer Research* 15(1):38-42, 2003.
- Thompson P., Balis F., Baruti M., Berg S.S., Adamson P., Klenk R., Aiken A., Packer R., Murry D.J., Jakacki R., Blaney S.M. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. *Cancer Chemother Pharmacol* (2003) 52:417-423.
- Finzer P., Stöhr M., Seibert N., Rösl F., Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number *J. Cancer Res. Clin. Oncol.* (2003) 129:107-113.
- Witt O, Mönkemeyer S, Rönndahl G, Erdlenbruch B, Reinhardt D, Kanbach K, and Pekrun A. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. *Blood*, Mar 2003; 101: 2001 - 2007.
- Svechnikova I, Gray S.G, Kundrotiene J, Ponthan F, Kogner P, Ekström T. Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. *Int. Journal of Oncology* 22: 579-588, 2003.
- Gray S.G., Iglesias A.H., Teh B.T., Dangond F., Modulation of Splicing Events in Histone Deacetylase 3 by Various Extracellular and Signal Transduction Pathways *Gene Expression*, Vol. 11, pp. 13-21. Oct. 2002.
- Baker M J, Brem S, Daniels S, Sherman B, Phuphanich S. Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate. *J Neuro-Oncology*; 59:239-242, 2002.

- Boivin A-J., Momparler L.F., Hurtubise A., Momparler R.L.. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. *Anti-Cancer Drugs*. Vol 13 (869-874) 2002.
- Dyer E.S., Paulsen M.T., Markwart S.M., Goh M., Livant D.L. and Ljungman M. Phenylbutyrate inhibits the invasive properties of prostate and breast cancer cell lines in the sea urchin embryo basement membrane invasion assay. *Int. J. Cancer*. 101, 496-499 (2002).
- Shi M-G, Huang Q., Dong J, Sun Z-F., Lan Q. Experimental Study of Combination Therapy against Human Glioma Xenograft by Differentiation-Inducing Agent and Cytotoxic Chemotherapeutic Drug. *Chinese Journal of Cancer*, 2002, 21(10): 190-1094.
- Du H-L., Qi Y., Shi Y-J., Bu D-F., Wu S-L. Apoptosis and Re-expression of p16 Gene in the Myeloma Cell Line U266 Induced by Synergy of Histone Deacetylase Inhibitor and Demethylating Agent. *Chinese Journal of Cancer*, 2002, 21(10):1057-1061.
- Kennedy C., Byth K., Clarke C.L., DeFazio A., Cell Proliferation in the Normal Mouse Mammary Gland and Inhibition by Phenylbutyrate. *Molecular Cancer Therapeutics* Vol. 1, 1025-1033, Oct. 2002.
- Sirchia S.M., Ren M., Pili R.ironi E., Somenzi G., Ghidoni R., Toma S., Nicolo G., Sacchi N.. Endogenous Reactivation of the RAR β 2 Tumor Suppressor Gene Epigenetically Silenced in Breast Cancer *Cancer Research* 62, 2455-2461, May 1, 2002.
- Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Zabalena Y, Hawkins AL, Burks K and Miller CB. Impact of prolonged infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clinical Cancer Research* Vol. 8, 963-970, April 2002
- Clarke K.O., Ludeman S.M., Springer J.B., Colvin O.M., Lea M.A., Harrison L.E. Exposure to a deuterated analogue of Phenylbutyrate retards S-phase progression in HT-29 colon cancer cells. *Journal of Pharmaceutical Sciences*, Vol. 91, No. 4, April 2002.
- Chang T-H, Szabo E., Enhanced Growth Inhibition by Combination Differentiation Therapy with Ligands of Peroxisome Proliferator-activated Receptor- γ and Inhibitors of Histone Deacetylase in Adenocarcinoma of the Lung. *Clinical Cancer Research* Vol. 8, 1206-1212, April 2002.
- Shao N, Huang Q, Sun J, Dong J, Wang A, Wang F, Zhu W, A putative pathway in differentiation of SHG-44 glioma cells induced by sodium phenylbutyrate. The Human Genome Organization, *HGM2002, Poster 451*
<http://hgm2002.hgu.mrc.ac.uk/Abstracts/Publish/WorkshopPosters/WorkshopPoster08/hgm0451.htm>
- Zhu Q, Zhang J-W, Zhu H-Q, Shen Y-L, Flexor M, Jia P-M, Yu Y, Cai X, Waxman S, Lanotte M, Chen S-J, Chen Z, and Tong J-H. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. *Blood*, Feb 2002; 99: 1014 - 1022.
- D-C Zhou, Kim SH, Ding W, Schultz C, Warrell R P, Jr, and Gallagher R E. Frequent mutations in the ligand-binding domain of PML-RAR α after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. *Blood*, Feb 2002; 99: 1356 - 1363.
- Feinman R., Clarke, K.O., Harrison LE. Phenylbutyrate-Induced Apoptosis is Associated with Inactivation of Nf- κ B in HT-29 colon cancer cells. *Cancer Chemother Pharmacol* (2002) 49:27-34.

- Goh M., Chen F., Paulsen M.T., Yeager A.M., Dyer E.S., Ljungman M. Phenylbutyrate Attenuates the Expression of Bcl-X_L, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells¹. *Neoplasia* Vol. 3, No. 4, 2001, pp. 331-338.
- Cosentini E, Haberl I, Pertschy P, Teleky B, Mallinger R, Baumgartner G, Wenzl E and Hamilton G. The differentiation inducers phenylacetate and phenylbutyrate modulate camptothecin sensitivity in colon carcinoma cells in vitro by intracellular acidification. *International Journal of Oncology* 19: 1069-1074, 2001
- Calvaruso G, Carabillo M, Guiliano M, Lauricella M, D'Anneo A, Vento R, Tesoriere G. Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: The effect of combined treatment with the topoisomerase I-inhibitor topotecan. *Int. Journal of Oncology* 18: 1233-1237, 2001.
- Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA: A Phase I Dose Escalation and Bioavailability Study of Oral Sodium Phenylbutyrate in Patients with Refractory Solid Tumor Malignancies. *Clin Cancer Res.* 7: 2292-2300, 2001.
- Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, Burks K, Miller CB: Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res.* 7: 2330-9, 2001
- Carducci MA, Gilbert J, Bowling MK, Noe D, Eisenberger MA, Sinibaldi V, Zabelina Y, Chen TL, Grochow LB, Donehower RC. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. *Clin Cancer Res.* 7(10):3047-55, Oct 2001
- Pili R, Kruszewski MP, Hager BW, Lantz J, Carducci MA. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. *Cancer Research* 61, 1477-85, Feb. 15, 2001.
- Berg S., Serabe B., Aleksic A., Bomgaars L., McGuffey L., Dauser R., Durfee J., Nuchtern J., Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. *Cancer Chemother Pharmacol.* 47: 385-390. February 2001.
- Reynolds S., Cederberg H., Chakrabarty S. Inhibitory effect 1-O (2 methoxy) hexadecyl glycerol and Phenylbutyrate on the malignant properties of human prostate cancer cells. *Clinical & Experimental Metastasis.* 18: 309-312. Dec 2000.
- Gore SD., Carducci MA., Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. *Expert Opin Investig Drugs.* (12):2923-34. Dec 2000.
- Davis T., Kennedy C., Chiew Y-E., Clarke C.L., and DeFazio A. Histone Deacetylase Inhibitors Decrease Proliferation and Modulate Cell Cycle Gene Expression in Normal Mammary Epithelial Cells. *Clinical Cancer Research* Vol. 6, 4334-4342, November 2000.
- Maslak P., Scheinberg D., Targeted therapies for the myeloid leukaemias. *Expert Opin Investig Drugs.* 9(6):1197-205 Jun 2000.

- Huang Y., Horvath CM, Waxman S. Regrowth of 5-Fluorouracil-treated Human Colon Cancer Cells is Prevented by the Combination of Interferon Gamma, Indomethacin, and Phenylbutyrate. *Cancer Res.* 60(12):3200-6. Jun 15, 2000.
- Fisher, J., Carducci, M., Baker, S., Phupanich, S., Grossman, St., Gilbert, M., Piantadosi, S. Dose Escalation Study of Oral Sodium Phenylbutyrate (PB) in Patients (Pts) with Refractory High Grade Astrocytomas (HGA): Maximum Tolerated Dose (MTD), Toxicity Profile, Pharmacology, and Survival. *Proc Am Soc Clin Oncol (ASCO)*19: 2000 (abstr 645).
- Chung YL., Lee YH., Yen SH., Chi KH., A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy. *Clin Cancer Res.* 6(4):1452-8. April 2000.
- Samid D., Wells M., Greene ME, Shen, W., Palmer CN, Thibault, A. Peroxisome Proliferator-activated Receptor Gamma as a Novel Target in Cancer Therapy: Binding and Activation by an Aromatic Fatty Acid with Clinical Antitumor Activity. *Clin Cancer Res.* 6(3):933-41. Mar 2000.
- Halicka H.D., Murakami T., Papageorgio C.N., Mittelman A., Mikulski S.M., Shogen K., Darzynkiewicz Z., Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. *Cell Prolif.* 2000, 33, 407-417.
- Ng AY, Bales W, Veltri RW. Phenylbutyrate-Induced Apoptosis and Differential Expression of Bcl-2, Bax, p53 and Fas in Human Prostate Cancer Cell Lines. *Analytical and Quantitative Cytology and Histology.* 2000 Feb; 22(1):45-54.
- Witzig T.E., Timm M., Stenson M., Kaufmann S.H. Induction of Apoptosis in Malignant B Cells by Phenylbutyrate or Phenylacetate in Combination with Chemotherapeutic Agents. *Clinical Cancer Research* 6(2): 681-92. Feb 2000.
- DiGiuseppe JA, Weng LJ, Yu KH, Fu S, Kastan MB, Samid, D., Gore, SD. Phenylbutyrate-induced G1 Arrest and Apoptosis in Myeloid Leukemia Cells: Structure-Function Analysis. *Leukemia* 13(8):1243-53. Aug 1999.
- Kebebew E., Wong M.G., Siperstein A.E., Duh, Q-Y and Clark, O.H. Phenylacetate Inhibits Growth and Vascular Endothelial Growth Factor Secretion in Human Thyroid Carcinoma Cells and Modulates Their Differentiated Function. *J Clin Endocrin Metab.* 84(8):2840-7. Aug 1999.
- Ozawa T., Lu, R.M., Hu LJ, Prados MD, Deen DF. Radiopotential of Human Brain Tumor Cells by Sodium Phenylacetate. *Cancer Letters.* 142(2):139-46. Aug 1999.
- Yu K.H., Weng L.J., Gore S.D. Augmentation of Phenylbutyrate -induced Differentiation of Myeloid Leukemia Cells Using all-*trans* Retinoic Acid. *Leukemia* 13(8):1258-65. Aug 1999.
- Redner RL, Wang J, and Liu JM. Chromatin Remodeling and Leukemia: New Therapeutic Paradigms. *Blood*, Jul 1999; 94: 417 - 428.
- Thibout D., Kraemer M, Di Benedetto, et al. Sodium Phenylacetate (NaPa) Induces Modifications of the Proliferation, the Adhesion and the Cell Cycle of Tumoral Epithelial Breast Cells. *Anti Cancer Research.* 19(3A):2121-6. May-Jun 1999.
- Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Rankin C, Prados MD. Phase II study of Phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. *J Clin Oncol.*, 17:984-990, Mar 1999.

- Lea M.A., Hodge, S. K., Randolph V.M. Induction of Histone Acetylation and Growth Regulation in Erythroleukemia Cells by 4-Phenylbutyrate and Structural Analogs. *UMDNJ - New Jersey Medical School, Newark, NJ. Anticancer Res.*, 19(3A):1971-6. 1999.
- Bar-Ner M, Thibault A, Tsokos M, Magrath IT, Samid D. Phenylbutyrate induces cell differentiation and modulates Epstein-Barr virus gene expression in Burkitt's lymphoma cells. *Clin Cancer Res.*, 5:1509-1516, 1999.
- Melchior SW, Brown LG, Figg WD, Quinn JE, Santucci RA, Brunner J, Thuroff JW, Lange PH, Vessella RL. Effect of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. *Int. J. Oncol.*, 14:501-508, 1999.
- Melichar B., Ferrandina G., Kudelka AP, et al. Growth Inhibitory Effects of Aromatic Fatty Acids on Ovarian Tumor Cell Lines. *Clin Cancer Res.*, 4:3069-3076 Dec 1998.
- Warrell R.P., He L.Z., Richon V, Calleja E., Pandolfi P.P., Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of Inhibitor of Histone Deacetylase. *J Natl Cancer Inst.*, 490(21):1621-5. Nov 1998.
- Huang Y., Waxman S. Enhanced Growth Inhibition and Differentiation of Fluorodeoxyuridine-treated Human Colon Carcinoma Cells by Phenylbutyrate. *Clin Cancer Res.*, 4 (10): 2503-9. Oct 1998.
- Harrison L., Wojciechowicz, D., Brennan, M., Paty, P. Phenylacetate Inhibits Isoprenoid Biosynthesis and Suppresses Growth of Human Pancreatic Carcinoma. *Surgery*, 124 (3):541-50. Sep 1998.
- Lea MA., Randolph VM., Induction of reporter gene expression by inhibitors of histone deacetylase. *Anticancer Res.* 18(4A):2717-22. July-Aug 1998.
- Darmaun D., Welch S., Rini A., et al Phenylbutyrate-induced Glutamine Depletion in Humans: Effect on Leucine Metabolism. *Am J Physiol* 274: E801-E807, 1998.
- List A.F., Hematopoietic Stimulation by Amifostine and Sodium Phenylbutyrate: What is the Potential in MDS? *Leuk Res.*, Suppl 22:S7-11. May 1998.
- Pelidis M.A., Carducci M.A., Simons J.W. Cytotoxic Effects of Sodium, Phenylbutyrate on Human Neuroblastoma Cell Lines. *Int. J. Oncol.*, 12 (4): 889-93. Apr 1998.
- Englehard H., Homer R.J., Duncan H., Rozental J. Inhibitory Effects of Phenylbutyrate on the Proliferation, Morphology, Migration and Invasiveness of Malignant Glioma Cells. *J. Neuro-Oncol.* 37:97-108, Apr 1998.
- Sidnell N, Chang B, Yamashiro JM, Wada RK. Transcriptional up-regulation of retinoic acid receptor β (RAR β) expression by Phenylacetate in human neuroblastoma cells. *Exp. Cell Res.*, 239:169-174, 1998.
- Gore Steven D., Dvorit Samid, and Li-Jun Weng Impact of the Putative Differentiating Agents Sodium Phenylbutyrate and Sodium Phenylacetate on Proliferation, Differentiation, and Apoptosis of Primary Neoplastic Myeloid Cells. *Clin Cancer Res.* 3:1755-1762. Oct 1997.
- Tong K.P., David-Beabes G., Meeker A., Bucci J., Deweese T., Carducci M. Phenylbutyrate (PB) has pleiotropic effects on gene transcription and inhibits telomerase activity in human prostate cancer. *Abstract of the 7th International Conference on Differentiation Therapy*, Oct 1997.

- Adam L., Crépin M., Israël L. Tumor Growth Inhibition, Apoptosis, and Bcl-2 Down-regulation of MCF-7ras Tumors by Sodium Phenylacetate and Tamoxifen Combination. *Cancer Res.*, 57:1023-1029. Mar 1997.
- Ferrandina G., Melichar B., Loercher AE, et al. Growth Inhibitory Effects of Sodium Phenylacetate (NSC3039) on Ovarian Carcinoma Cell in Vitro. *Cancer Res.*, 57(19): 4309-15. Mar 1997.
- Carducci MA, Bowling MK, Eisenberger M, Sinibaldi V, Chen T, Noe D, Growthow L, Donehower R. Phenylbutyrate (PB) for refractory solid tumors: Phase I clinical and pharmacological evaluation of intravenous and oral PB. *Anticancer Res.*, 17:3921-3982, 1997.
- Miller AC, Whittaker A, Thibault A, Samid D. Modulation of radiation response of human tumor cells by the differentiation inducers, Phenylacetate. *Int J Radiat Biol*, 72:211-218. 1997.
- Samid D, Hidgins WR, Shack S, Liu L, Prasanna P, Myers CE. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. *Adv. Exp. Med. Biol.*, 400A:501-505, 1997.
- Boudoulas S., Lush RM., McCall N.A., Samid D., Reed E., Figg WD. Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two Novel Antineoplastic Agents. *Ther Drug Monit.*, 18:714-720. Dec 1996.
- Gorospe M., Shack S. Guyton K.Z., Samid D., Holbrook N.J. Up-regulation and Functional Role of p21^{Waf1/Cip1} During Growth Arrest of Human Breast Carcinoma MCF-7 Cells by Phenylacetate. *Cell Growth Differ.* 7(12): 1609-1615. Dec 1996.
- Shack S., Miller A., Liu L., Thibault A., Prasanna P., Samid D. Vulnerability of Multidrug-resistant Tumor Cells to the Aromatic Fatty Acids Phenylacetate and Phenylbutyrate. *Clin. Cancer Res.*, 2:865-872. May 1996.
- Danesi R, Nardini D, Basolo F, Del Tacca M, Samid D, Myers CE. Phenylacetate inhibits isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene. *Mol. Pharmacol.*, 49:972-979, Mar 1996.
- Carducci MA, Nelson J, Chan-Tack K, Ayyagari S, Sweatt W, Campbell P, Nelson W, Simons J. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than Phenylacetate. *Clin Cancer Res.*, 2:379-387, Feb 1996.
- Johnson DE, Ochieng J, Evans SL. Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative breast cancer cells or normal breast epithelial cells. *Anticancer Drug*, 7:288-292. 1996.
- Prasanna P., Thibault A., Liu L., Samid D. Lipid Metabolism as a Target for Brain Cancer Therapy: Synergistic Activity of Lovastatin and Sodium Phenylacetate Against Human Glioma Cells. *J. Neurochem.*, 66: 710-716. 1996.
- Pineau T., Hudgins W., Liu L., Chen L., Sher T., Gonzales F., Samid D. Activation of a Human Peroxisome Proliferator-Activated Receptor by the Antitumor Agent Phenylacetate and its Analogs. *Biochemical Pharmacol.*, 52:659-667. 1996.
- Walls R., Thibault A., Liu L., Wood C., Kozlowski J.M., Figg W.D., Sampson M.L., Elin R.J., and Samid D. The Differentiating Agent Phenylacetate Increases Prostate-Specific Antigen Production by Prostate Cancer Cells. *The Prostate* 29:177-182 (1996).
- Maestri NE., Clissold DB., Brusilow SW., Long-term survival patients with argininosuccinate Synthetase deficiency. *J Pediator.*, 127(6):929-35. Dec. 1995.

- Adam L., Crépin M., Savin C., Israël L. Sodium Phenylacetate Induces Growth Inhibition and Bcl-2 Down-regulation and Apoptosis in MCF7 ras Cells *in Vitro* and in Nude Mice. *Cancer Res.*, 55: 5156-5160. Nov 1995.
- Prasanna P., Shack S., Wilson V., Samid D. Phenylacetate in Chemoprevention: *in vitro* and *in vivo* Suppression of 5-Aza-2'-Deoxycytidine-induced Carcinogenesis. *Clin Cancer Res.*, 1:865-871, Aug 1995.
- Liu L., Hudgins R., Miller A., Samid D. et al Transcriptional Upregulation of TGF- α by Phenylacetate and Phenylbutyrate is Associated with Differentiation of Human Melanoma Cells. *Cytokine.*, 7:449-456, Jul 1995.
- Thibault A., Samid D., Cooper M., Figg W., et al. Phase I Study of Phenylacetate Administered Twice Daily to Patients with Cancer. *Cancer.*, 75:2932-2938, Feb 1995.
- Hudgins W., Shack S., Myers C., Samid D. Cytostatic Activity of Phenylacetate and Derivatives Against Tumor Cells: Correlation with Lipophilicity and Inhibition of Protein Prenylation. *Biochemical Pharmacol.*, 50:1273:1279. 1995.
- Newmark H., Young C. Butyrate and Phenylacetate as Differentiating Agents: Practical Problems and Opportunities. *J. Cell. Biochem.*, Suppl. 22:247-253. 1995.
- Piscitelli S., Thibault A., Figg W., et al. Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. *J. Clin. Pharmacol.*, 35:368-373. 1995.
- Shack S., Chen L., Miller A., Danesi R., Samid D. Increased Susceptibility of *ras*-transformed Cells to Phenylacetate is Associated with Inhibition of p21^{ras} Isoprenylation and Phenotypic Reversion. *Int. J. Cancer.*, 63:124-129. 1995.
- Sidell N., Wada R., Han G., Chang B., Shack S., Moore T., Samid D. Phenylacetate Synergizes with Retinoic Acid in Inducing Differentiation of Human Neuroblastoma Cells. *Int. J. Cancer.*, 60: 507-14. 1995.
- Stockhammer G., Manley, G. T., Johnson R., Rosenblum M., Samid D., Lieberman F. Inhibition of Proliferation and Induction of Differentiation in Medulloblastoma and Astrocytoma-derived Cell Lines with Phenylacetate. *J. Neurosurgery.*, 83:672-81. 1995.
- Lea MA, Tulsyan N. Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. *Anticancer Res.*, 15:879-883, 1995.
- Thibault A., Cooper M., Figg W., Venzon D. A Phase I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients with Cancer. *Cancer Res.*, 54:1690-94. Apr 1994.
- Samid D., Ram Z., Hudgins W.R., Shack S., Liu, L., Walbridge S., Oldfield E., Myers C. Selective Activity of Phenylacetate Against Malignant Gliomas: Resemblance to Fetal Brain Damage in Phenylketonuria. *Cancer Res.*, 54:891-95, Feb 1994.
- Ram Z., Samid D., Walbridge S., Oshiro E., et al. Growth Inhibition, Tumor Maturation and Extended Survival in Experimental Brain Tumors in Rats Treated with Phenylacetate. *Cancer Res.* 54:2923-27. 1994.
- Liu L., Shack S., Stetler-Stevenson W., Hudgins W., Samid D. Differentiation of Cultured Human Melanoma Cells Induced by the Aromatic Fatty Acids Phenylacetate and Phenylbutyrate. *J. Invest. Dermatol.*, 103:335-340. 1994.

- Call CDRT, Stenson MJ, Witzig TE. Effects of Phenylacetate on cells from patients with B-chronic lymphocytic leukemia. *Luk Lymphoma*. 14:145-149, 1994.
- Figg W, Walls R, Cooper M, Thibault A, Sartor O, McCall N, Myers C, Samid D. In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate. *Anticancer Drugs*, 5:336-342, 1994.
- Samid D, Shack S, Myers CE. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of Phenylacetate. *J. Clin. Invest.*, 91:2288-2295, May 1993.
- Cinatl Ji., Cinatl Ja, Mainke M., et al. *In vitro* Differentiation of Human Neuroblastoma Cells Induced by Sodium Phenylacetate. *Cancer Letters.*, 70: 15-24. 1993.
- Samid D., Yeh A., Prasanna P. Induction of Erythroid Differentiation and Fetal Hemoglobin Production in Human Leukemic Cells Treated with Phenylacetate. *Blood*. 80: 1576-1581, Sep 1992.
- Samid D., Shack S., Sherman L. Phenylacetate - a Novel Nontoxic Inducer of Tumor Cell Differentiation. *Cancer Res*. 52:1988-92. Apr 1992.

BLOOD

- Almeida, A., Murakami, Y., Baker, A., Maeda, Y., Roberts, I., Kinoshita, T., Layton, DM, Karadimitria, A. Targeted Therapy for Inherited GPI Deficiency. *The New England Journal of Medicine* 2007; 356:1641-7
- Imedia, A., Murakami, Y., Baker, A., Maeda, Y., Roberts, I., Kinoshita T., Layton, D., Karadimitria, A. *The New England Journal of Medicine* 356;16, April 19, 2007

SICKLE CELL ANEMIA, THALASSEMIA & COOLEY'S ANEMIA

- Perrine SP. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. *Pediatr Ann* 2008; 37 (5): 339-346.
- Hines P, Dover GJ, Resar LMS. Pulsed-dosing with oral sodium Phenylbutyrate increases hemoglobin F in a patient with sickle cell anemia. *Pediatr Blood Cancer* 2008; 50 (2): 357-359.
- Xing H, Zhang S, Koeffler HP, Fung, MC. Cucurbitacin D Upregulates fetal hemoglobin expression in K562 cells and human erythroid progenitors. *Blood* 2007; 110 (11, Part 2): 26B-27B
- Odièvre M, Brun M, Krishnamoorthy R, lapoumériou and Elion J. Sodium Phenylbutyrate Downregulates Endothelin-1 Expression in Cultured Human Endothelial Cells: Relevance to Sickle-Cell Disease. *American Journal of Hematology*, 82:357-362, 2007.
- Perrine S, Trudel M, Castaneda SA, Mankidy R, Boosalis MS, Mpollo M-SEM, White GL, Bohacek R, Faller DV. A new generation of gamma globin gene inducers act on novel molecular and cellular targets. *Blood* 2006; 108 (11, Part 1): 453A.

- Thompson AA. Advances in the management of sickle cell disease. *Pediatr Blood Cancer* 2006; 45 (5): 533-539.
- Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP. Fetal haemoglobin augmentation in E/ β^0 thalassaemia: clinical and haematological outcome. *British Journal of Haematology*, 2005, 131, 378-388
- Witt, Olaf, Mönkemeyer, Sven, Rönndahl, Gabi, Erdlenbruch, Bernhard, Reinhardt, Dirk, Kanbach, Katrin and Pekrun, Arnulf. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. *Blood*, March 1, 2003, Volumb 101, Number 5
- Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, and Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. *Blood*, 15 December 2002, Vol. 100, No. 13, pp. 4640-4648
- Resar LMS, Fitzpatrick LK, Friedmann AM, Brusilow SW, Dover GJ. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on oral sodium phenylbutyrate. *Blood – Abstract* #1849. Vol. 94:417a.
- Hoppe C., Vichinsky E., Lewis B., Foote D., Styles L. Hydroxyurea and Sodium Phenylbutyrate Therapy in Thalassaemia Intermedia. *Am J Hematol.*, 62(4):221-7. Dec 1999.
- Olivieri, NF and Weatherall, DJ. The Therapeutic Reactivation of Fetal Haemoglobin. *Human Molecular Genetics*, 1998, Vol.7, No. 10 Review 1655-1658.
- MacMillan ML, Fouladi M., Nisbet-Brown E., Waye JS, Oliveri, NF Treatment of Two Infants with Cooley's Anemia with Sodium Phenylbutyrate. *Ann N Y Acad Sci.*, 850:452-4. Jun 1998.
- Dover GJ Hemoglobin Switching Protocols in Thalassaemia. Experience with Sodium Phenylbutyrate and Hydroxyurea. *Ann N Y Acad Sci.*, 850:80-6. Jun 1998.
- Oliveri NF, Rees, DC, Ginder GD, Thein SL, Waye JS, Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemia. *Ann N Y Acad Sci.*, 850:100-9. Jun 1998.
- Olivieri NF, Rees D.C., Ginder G.D., et al. Treatment of Thalassaemia Major with Phenylbutyrate and Hydroxyurea. *Lancet.*, 350: 491-492. Aug 1997.
- Hudgins WR, Fibach E., Safaya S., Rieder R.F., Miller, A.C., Samid D. Transcriptional Upregulation of γ -Globin by Phenylbutyrate and Analogous Aromatic Fatty Acids. *Biochem Pharmacol.*, 52: 1227-1233. Oct 1996.
- Collins A.F., Pearson H.A., Giardina P., McDonagh KT., Brusilow SW., Dover G.J. Oral Sodium Phenylbutyrate Therapy in Homozygous β Thalassaemia: A Clinical Trial. *Blood.*, 85: 43-49. 1995.
- Dover G.J., Brusilow, S., Charache S., Induction of Fetal Hemoglobin Production in Subjects with Sickle Cell Anemia by Oral Sodium Phenylbutyrate. *Blood.*, 184(1):339-43. Jul 1994.
- Fibach E., Prasanna P., Rodgers G., Samid D. Enhanced Fetal Hemoglobin Production by Phenylacetate and 4-Phenylbutyrate in Erythroid Precursors Derived from Normal Donors and Patients with Sickle Cell Anemia and β Thalassaemia. *Blood.*, 82:2203-09. 1993.
- Perrine, Susan P. Fetal Globin Induction – Can it Cure β Thalassaemia? *American Society of Hematology* Dover D., Brusilow S., Samid D. Increased Fetal Hemoglobin in Patients Receiving Sodium 4-Phenylbutyrate. *New Eng. J. Med.*, 327:569-570, Oct 1992.

Leary, W.E. Cancer Drug Also Helps in Treating Sickle Cell Anemia, Researchers Say. *Atlanta Journal*, Sect E10. Aug 1992.

Smigel K. Non-toxic Drug Being Tested to Treat Cancer and Anemias. *J Natl Cancer Inst.*, 84(18):1398-9. Sep 1992.

UREA CYCLE DISORDER/ ORNITHINE TRANSCARBAMYLASE DEFICIENCY

Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Batshaw ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. Urea Cycle Disorders Consortium of the Rare Diseases Clinical Work Network, *Mol Genet Metab* 2008; 94 (4): 397-402.

Leonard JV, Ward P, Martin P, Morris AAM. Hypothesis: proposals for the management of a neonate at risk of hyperammonaemia due to a urea cycle disorder. *Eur J Pediatr* 2008; 167 (3): 305-309.

Lee B, Garovoy MR, Gargosky SE, Berry SA. Preliminary data on adult patients with urea cycle disorder (UCD) in an open-label, switch-over, dose-escalation study comparing a new ammonia scavenger glyceryl tri (4-phenylbutyrate) (HPN-100), to buphenyl (sodium phenylbutyrate – PBA). *Journal of Inherited Metabolic Disease* 2008; 31 (Suppl. 1): 91.

Dobbelaere DD. Sodium phenylbutyrate (Ammonaps) in the treatment of patients with urea cycle disorders – European post-approval data. *Journal of Inherited Metabolic Disease* 2008; 31 (Suppl. 1): 92.

Maillot F, Crenn P. Urea cycle disorders in adult patients. *Revue Neurologique (Paris)* 2007; 163 (10): 897-903.

Bhattacharya K, Briddon A, Lee PJ. A review of biochemical outcomes of adults with OTC deficiency. *Journal of Inherited Metabolic Disease* 2007; 30 (Suppl. 1): 82.

Wright GA, Davies NA, Ytrebo LM, Stadlbaure V, Fuskevag O-m, Zwigmann C, Hodges S, Jalan R. L-ornithine Phenylacetate reduces arterial ammonia, improves brain osmolytes and reduces brainwater in a bile duct ligated rat model of cirrhosis. *Hepatology* 2007; 46 (4, Suppl S): 604A-605A.

Kern RM, Yang Z, Kim PS, Grody WW, Iyer RK, Cederbaum SD. Arginase induction by sodium phenylbutyrate in mouse tissues and human cell lines. *Molecular Genetics and Metabolism* 90 (2007) 37.41.

Eather G, Coman D, Lander C, J. McGill Carbamyl phosphate synthase deficiency: Diagnosed during pregnancy in a 41-year-old. *Case Reports/Journal of Clinical Neuroscience* 13 2006: 702-706.

Singh RH, Acosta PB, Kennedy MP, Longo N, Elsas LJ. Potassium retention in patients treated for argininosuccinate lyase deficiency. *Journal of Inherited Metabolic Disease* 2006; 29 (1): 48.

Wuebbels BH. Outcomes among male OTC patients treated with Ammonaps. *Journal of Inherited Metabolic Disease* 2006; 29 (Suppl 1): 129.

- Saha AS, Langridge P, Playfor SD. The pattern of intravenous drug administration during the transfer of critically ill children by a specialist transport team. *Paediatr Anaesth* 2006; 16 (10):1063-1067
- CVilatoba M, Eckstein C, Bilbao G, Smyth CA, Jenkins S, Thompson JS, Eckhoff De, Contreras JL. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum stress mediated apoptosis. *Surgery* 2005; 138 (2): 342-351.
- Bachmann C. Long-term outcome of urea cycle disorders. *Acta Gastroenterol Belg* 2005; 68 (4): 466-468.
- Horslen S.P., McCowan T.C., Goertzen T.C., Warkentin P.I., Cai H.B., Strom S.C., Fox I.J. Isolated Hepatocyte Transplantation in an Infant with Severe Urea Cycle Disorder. *Pediatrics* Vol. 111 No. 6 June 2003.
- Legras A., Labarthe F., Maillot F., Garrigue M-A., Kouatchet A., Ogier de Baulny H., Late diagnosis of ornithine transcarbamylase defect in three related female patients: Polymorphic presentations. *Crit. Care Med.* 2002 Vol. 30, No. 1.
- Burlina A.B., Ogier H., Korall H., Trefz F.K. Long-term treatment with Sodium Phenylbutyrate in ornithine transcarbamylase-deficient patients. *Molecular Genetics and Metabolism* 72, 3512-355 March 2001
- Batchaw ML., MacArthur RB, Tuchman M., Alternative pathway therapy for urea cycle disorders: twenty years later. *J Pediatr.*, 138 (1 Suppl):S46-54; discussion S-54-5. Jan 2001.
- Summar M., Current strategies for the management of neonatal urea cycle disorders. *J. of Pediatrics*, (138: S30-S39) Jan. 2001.
- Praphanphoj V, Boyadjiev SA, Waber LJ, Brusilow SW, Geraghty MT. Three cases of intravenous sodium benzoate and sodium Phenylacetate toxicity occurring in the treatment of acute hyperammonaemia. *J. Inherit Metab. Dis.*, 23:129-136. 2000.
- Redonnet-Vernhet, I., Rouanet, F., Pedespan, J.M., Hocke, C. And Parrot, F. A Successful pregnancy in a heterozygote for OTC deficiency treated with sodium phenylbutyrate. *Neurology* 54, February 2000.
- Bogdanovic M.D., Kidd D., Briddon A., Duncan J.S., Land J.M. Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus. *J. Neurol Neurosurg. Psychiatry* 2000; 69:813-815.
- Redonnet-Vernhet I., Rouanet F., Pedespan JM, Hocke, C., Parrot F., A Successful Pregnancy in a Heterozygote for OTC Deficiency Treated with Sodium Phenylbutyrate. *Neurology.*, 54(4):1008. Feb 2000.
- Brunquell P., Tezcan K., DiMarion FJ., Electroencephalographic findings in ornithine transcarbamylase deficiency. *J Child Neurol.*, 14(8):533-6. Aug 1999.
- Yudkoff M., Daikhin Y., Nissim I., Jaward A., Wilson J., Batshaw M., In vivo nitrogen metabolism in ornithine transcarbamylase deficiency. *J Clin Invest.*, 98(9)2167-73. Nov 1996.
- Maestri NE., Brusilow SW., Clissold DB., Bassett SS., Long-term treatment of girls with ornithine transcarbamylase deficiency. *N Engl J Med.*, 19; 335(12):855-9. Sep 1996.
- Sodium Phenylbutyrate for Urea Cycle Enzyme Deficiencies. *Med Lett Drugs Ther.*, 38(988):105-6. Nov 1996.

- Brusilow SW, Maestri NE. Urea cycle disorders: Diagnosis, pathophysiology, and therapy. *Adv. Pediatr.*, 43:127-170. 1996.
- Maestri NE, Clissold DB, Brusilow SW. Long-term survival of patients with argininosuccinate synthetase deficiency. *The Journal of Pediatrics*, 929-935. Dec 1995.
- Gutteridge C, Kuhn RJ. Compatibility of 10% sodium Benzoate plus 10% sodium Phenylacetate with various flavored vehicles. *Am J Hosp Pharm*; 2508-2509. 1994.
- Brusilow SW., Finkelstien J., Restoration of nitrogen homeostasis in man with ornithine transcarbamylase deficiency. *Metabolism.*, 42(10):1336-9. Oct 1993.
- Brusilow S. Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion. *Ped. Res.*, 29(2):147-150. 1991.
- Brusilow S. "Treatment of Urea Cycle Disorders." Treatment of Genetic Disease (RJ Desknick ed) Churchill-Livingston, p79-94. 1991.
- Maestri N., Hauser E., Bartholomew D., Brusilow S. Prospective Treatment of Urea Cycle Disorders. *J Ped.*, 119(6):923-928. 1991.
- Rubenstein J.L.R., Johnston K., Elliot G.R., Brusilow S.R. Haloperidol-induced Hyperammonaemia in a Child with Citrullinaemia. *J. Inher. Metab. Dis.*, 13: 754-755. 1990.
- Brusilow S., Danney M., Waber L., Batshaw M., et al Treatment of Episodic Hyperammonemia in Children with Inborn Errors of Urea Synthesis. *N Engl J Med.*, 310:1630-34. Jun 1984.
- Batshaw M.L., Brusilow S.W. Evidence of Lack of Toxicity of Sodium Phenylacetate and Sodium Benzoate in Treating Urea Cycle Enzymopathies. *J. Inher. Metab. Dis.*, 4:231. 1981.

LEUCINE METABOLISM

- Marini JC, Lanpher B, Scaglia F, Carter S, Garlick PJ, Jahoor F, Lee B. Phenylbutyrate reduces plasma leucine concentrations without affecting the flux of leucine. *FASEB Journal* 2007; 21 (5): A335.

LIPOPROTEIN RECEPTOR

- Tveten K, Holla OL, Ranheim T, Berge KE, Leren TP, Kulseth MA. Rescue of the low density lipoprotein receptor 2A mutant G544V by 4-phenylbutyrate. *Molecular chaperones and the heat shock response* 2006; 187.
- Tveten K, Holla OL, Ranheim T, Berge KE, Leren TP, Kulseth MA. 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. *FEBS J* 2007; 274 (8): 1881-1893.

BENIGN PROSTATE HYPERPLASIA (BPH)

Carducci, M.A., Yang Q., Kruszewski, M., Rodriguez, R., Androgen-insensitive prostate-specific promoter/enhancer gene therapy constructs are inducible with the differentiation agent, phenylbutyrate. *Proceedings of the American Association for Cancer Research*. Vol 40. April 1999.

Lipschutz J.H., Samid D, Cunha G.R. Phenylacetate is an Inhibitor of Prostatic Growth and Development in Organ Culture. *J Urol.*, 155:1762-1770. May 1996.

CYSTIC FIBROSIS

Roque, T., Boncoeur, E., Saint-Criq, V., Bonvin, E., Clement, A., Tabary, O., Jacquot, J. Pro-inflammatory effect of sodium 4-phenylbutyrate in $\Delta F508$ -CFTR lung epithelial cells: Involvement of ERK1/2 and JNK signaling. *JPET*, June 23, 2008, DOI:10.1124/jpet.107.135186

Singh OV, Pollard HB, Zeitlin, PL. Chemical Rescue of $\Delta F508$ -CFTR Mimics Genetic Repair in Cystic Fibrosis Bronchial Epithelial Cells. *Molecular & Cellular Proteomics* 7.5, February, 2008.

Virginie Prulièr-Escabasse, Carole Planés, Estelle Escudier, Pascale Fanen, André Coste, Christine Clerici. Modulation of Epithelial Sodium Channel Trafficking and Function by Sodium 4-Phenylbutyrate in Human Nasal Epithelial Cells. *JBC Papers in Press*, September 21, 2007, DOI 10.1074/jbc.M702384200.

Claudiu Iordache, Marek Duszyk. Sodium 4-Phenylbutyrate upregulates EnaC and sodium absorption in T84 cells. *Experimental Cell Research* 313 (2007) 305-311

Vij, Neeraj, Fang, Shengyun and Zeitlin, Pamela L. Selective Inhibition of Endoplasmic Reticulum-associated Deradation Rescues $\Delta F508$ -Cystic Fibrosis Transmembrane Regulator and Suppresses Interleukin-8 Levels. *The Journal of Biological Chemistry*, Vol. 281, No. 25 pp. 17369-17378, June 23, 2006.

Singh O.V., Vij N., Mogayzel Jr. P.J., Jozwik C., Pollard H.B., Zeitlin P. L., Pharmacoproteomics of 4-Phenylbutyrate-treated IB3-1 Cystic Fibrosis Bronchial Epithelial Cells. *Journal of Proteome Research* 2006, 5, 562-571.

Kerem E. Pharmacological Induction of CFTR Function in Patients with Cystic Fibrosis: Mutation-Specific Therapy. *Pediatric Pulmonology* 40:183-196 (2005).

Céline René, Magali Taulan, Florence Iral, Julien Doudement, Aurore L'Honoré, Catherine Gerbon, Jacques Demaille, Mireille Claustres and Marie-Catherine Romey, Binding of serum response factor to cystic fibrosis transmembrane conductance regulator CArG-like elements, as a new potential CFTR transcriptional regulation pathway. *Nucleic Acids Research*, Vol. 33, No. 16, 5271-5290, 2005.

Suaud L, Rubenstein RC. Activation of STAT-3 in CF epithelial cell by Sodium 4-Phenylbutyrate. *FASEB Journal* 2005; 19 (4, Suppl. S, Part 1): A658.

- Wright J.M., Zeitlin P.L., Cebotaru L., Guggino S.E., Guggino W.B., Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. *Physiol Genomics* 16:204-211, 2004.
- Lim M., McKenzie K., Floyd A.D., Kwon E., Zeitlin P.L. Modulation of $\Delta F508$ Cystic Fibrosis Transmembrane Regulator Trafficking and Function with 4-Phenylbutyrate and Flavonoids. *Am. J. Respir. Cell Mol. Biol.* Vol. 31, pp. 351-357, 2004.
- Wang W-J., Mulugeta S., Russo S.J., Beers M.F., Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative, *Journal of Cell Science* 116, 683-692, 2003.
- Roomans G.M. Pharmacological Approaches to Correcting the Ion Transport Defect in Cystic Fibrosis. *Am J. Respir Med.* 2003; 2(5):413-431
- Poschet J.F., Skidmore J., Bouchjer J.C., Firoved A.M., Van Dyke R.W., Deretic V. Hyperacidification of Cellubrevin Endocytic Compartments and Defective Endosomal Recycling in Cystic Fibrosis Respiratory Epithelial Cells, *The Journal of Biological Chemistry* Vol. 277, No. 16, April 2002.
- Zeitlin, P., Diener-West, M., Rubenstein, R., Boyle, M., Lee, C., Brass-Ernst, L. Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate. *Molecular Therapy*, Vol. 6, No. 1, July 2002
- Farinha Carols M., Nogueira, Paulo, Mendes, Filipa, Penque, Deborah and Amaral, Margarida D. The human Dnaj homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the *in vivo* stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. *Biochem. J.* (2002) 366, 797-806.
- Choo-Kang L.R., Zeitlin P.L. Induction of HSP70 promotes $\Delta F508$ CFTR trafficking. *Am J. Physiol Lung Cell Mol Physiol* 281:L58-L68, 2001.
- Rubenstein R.C., Lyons B.M. Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. *Am J. Physiol Lung Cell Mol Physiol* 281:L43-L51, 2001.
- Poschet J.F., Boucher J.C., Tatterson L., Skidmore J., Van Dyke R.W., Deretic V., Molecular basis for defective glycosylation and Pseudomonas pathogenesis in cystic fibrosis lung *PNAS*, Nov. 20, 2001, Vol. 98, No. 24.
- Oldendorf B., Cover Story: Therapeutic Development Network Enhances Cystic Fibrosis Research. *NCRR Reporter, Winter 2001, Cover Story* (<http://www.ncrr.nih.gov/newspub/jan01rpt/Cystic.asp>).
- McGrath-Morrow SA, Stahl JL. G(1) Phase growth arrest and induction of p21(Waf1/Cip1/Sdi1) in IB3-1 cells treated with 4-Sodium Phenylbutyrate. *J Pharmacol Exp Ther.*, 294(3):941-7. Sep 2000.
- Andersson, G.M. Roomans. Activation of $\Delta F508$ CFTR in a cystic fibrosis respiratory epithelial C. cell line by 4-phenylbutyrate, genistein and CPX. *European Respiratory Journal* Vol.15 Issue 5 Pg 937 - May 2000.
- Rubenstein R.C, Zeitlin P.L., Sodium 4-phenylbutyrate Downregulates Hsc70: Implications for Intracellular Trafficking of $\Delta F508$ -CFTR. *Am J Physiol Cell Physiol.*, 278(2):C259-67. Feb 2000.
- Zeitlin PL, Pharmacological Restoration of $\Delta F508$ CFTR-mediated Chloride Current. *Kidney Int.*, 7(3):832-7. Mar 2000.

- Bradbury N.A., Focus on "Sodium 4-phenylbutyrate Downregulates Hsc70: Implications for Intracellular Trafficking of Δ F508-CFTR." *Am J Physiol Cell Physiol.*, 278(2):C257-8. Feb 2000.
- Oldendorf B., Cover Story: Therapeutic Development Network Enhances Cystic Fibrosis Research. *NCRR Reporter, Winter 2001, Cover Story* (<http://www.ncrr.nih.gov/newspub/jan01rpt/Cystic.asp>).
- Loffing J., Moyer B.D., Reynolds D., Stanton B.A., PBA Increases CFTR Expression but at High Doses Inhibits C1(-) Secretion in Calu-3 Airway Epithelial Cells. *Am J. Physiol.*, 277(4 Pt 1):L700-8. Oct 1999.
- Rubenstein R.C., Zeitlin P.L., A Pilot Clinical Trial of Oral Sodium 4-phenylbutyrate (Buphenyl) in Δ F508-Homozygous Cystic Fibrosis Patients: Partial Restoration of Nasal Epithelial CFTR Function. *Am J Respir Crit Care Med.*, 157(2):484-90. Feb 1998.
- Rubenstein R.C., Zeitlin, P.L. Use of Protein Repair Therapy in the Treatment of Cystic Fibrosis. *Curr Opin Pediatr.*, 10(3):250-5. Jun 1998.
- Friend, T. Treatment of Cystic Fibrosis on the Fast Track. *USA TODAY, 7D.* Apr 1998.
- Rubenstein R.C., Egan M.E., Zeitlin P.L. *In vitro* Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells Containing Δ F508-CFTR. *J Clin Invest.*, 100:2457-2465. Nov 1997.

FAMILIAL HYPERCHOLESTEROLEMIA

- Tveten, K., Holla, Ø.L., Ranheim, T., Berge, K.E., Leren, T.P., Kulseth, M.A. 4-Phenylbutyrate restores the functionality of a misfolded mutant low-density lipoprotein receptor. *FEBS Journal*, 274 (2007), 1881-1893.

PHENYLKETONURIA

- Nascimento, C., Leandro, J., de Almeida, I.T., Leandro, P., Modulation of the Activity of Newly Synthesized Human Phenylalanine Hydroxylase Mutant Proteins by Low-Molecular-Weight Compounds. *Protein Journal* (2008) 27:392-400.

LUNG/ABCA3 DEFECTS

- Cheong, N., Madesh, M., Gonzales, L.W., Zhao, M., Yu, K. Ballard, P.L., Shuman, H. Functional and Trafficking Defects in ABCA3 mutants associated with Respiratory Distress Syndrome. *The Journal of Biological Chemistry*, January 16, 2006

ADRENOLEUCODYSTROPHY (ALD)

- Gondcaille C., Depreter M., Fourcade S., Lecca M.R., Leclercq S., Martin P.G.P., Pineau T., Cadepond F., ElEtr M., Bertrand N., Beley A., Duclos S., De Craemer D., Roels F., Savary S., Bugaut M., Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. *The Journal of Cell Biology*, Vol. 169, No. 1, 93-104, April 2005.
- Wei H., Kemp S., McGuinness MC, Moser AB, Smith KD. Pharmacological induction of Peroxisomes in Peroxisome Biogenesis Disorders. *Ann Neurol*, 47:286-296. 2000.
- Kemp S., Wei H.M., Lu J.F., et al Gene Redundancy and Pharmacological Gene Therapy: Implications for X-link Adrenoleucodystrophy. *Nat Med.*, 4(11):1261-8. Nov 1998.
- Wanders, R.J.A. A Happier Sequel to Lorenzo's Oil? *Nat Med.*, 4(11):1245-6. Nov 1998.

KIDNEY

- Choi S.W., Ryu O.H., Choi S.J., Song I.S., Bleyer A.J., Hart T.C. Mutant Tamm-Horsfall Glycoprotein Accumulation in Endoplasmic Reticulum Induces Apoptosis Reversed by Colchicine and Sodium 4-Phenylbutyrate. *J. Am. Soc. Nephrol.* 16:3006-3014, 2005.
- Liu Xiao Li, Nephtrin cellular trafficking and intracellular interactions, Division of Matrix Biology Dept. of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, May 2004.
- Liu X.L., Cotta Done S., Yan K., Kilpelainen P., Pikkarainen T., Tryggvason K. Defective Trafficking of Nephtrin Missense Mutants Rescued by a Chemical Chaperone. *J. Am. Soc. Nephrol.* 15:1731-1739, 2004.

BLADDER DYSFUNCTION

- Sawada N, Yao J, Hiramatsu N, Hayakawa K, Zakoji H, Kobayashi H, Mochizuki T, Araki Im Takeda M, Kitamura M. A novel target for boo-induced bladder dysfunction. *European Urology Supplements* 2008; 7 (3): 265.

AMYOTROPHIC LATERAL SCLEROSIS (ALS)

- Scott, S, Kranz, JE, Cole, J, Lincecum, JM, Thompson, K, Kelly, N, Bostrom, A, Theodoss, J, Al-Nakhala, BM, Vieira FG, Ramasubbu, J, Heywood, JA. Design, power and interpretation of studies in the standard murine model of ALS. *Amyotroph Lateral Scler* 2008; 9 (1): 4-15.

- Cudkowicz, ME, Andres, PL, Choudry, R, MacDonald, SA, Zhang, H, Schoenfeld, D, Ferrante, RJ. Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS *Neurology* 2007; 68 (12, Suppl. 1): A90.
- Petri S., Kiaei M., Kipiani K., Chen J., Calingasan N.Y., Crow J.P., Beal M.F., Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. *Neurobiology of Disease* 22, 40-49 (2006).
- Carri, MT, Grignaschi, G, Bendotti, C. Targets in ALS: designing multidrug therapies. *Trends Pharmacol Sci* 2006; 27 (5): 267-273.
- Traynor, BJ, Bruijn, L, Conwit, R, Beal, F, O'Neill, G, Fagan, SC, Cudkowicz, ME. *Neurology* 2006; 67 (1): 20-27.
- Bruijn LI, Cudkowicz, M. Therapeutic targets for amyotrophic lateral sclerosis: Current treatments and prospects for more effective therapies. *Expert Rev Neurother* 2006; 6 (3): 417-428.
- DiBernardo, A.B., Cudkowicz, M.E. Translating preclinical insights into effective human trials in ALS. *Biochimica et Biophysica Acta* 1762 (2006) 1139-1149.
- Ryu H, Smith K, Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown Jr. R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. *Journal of Neurochemistry*, 2005, 93, 1087-1098.

BRAIN DISORDERS

- Pahan K., Sheikh F.G., Namboodiri A.M.S., Singh I., Lovastatin and Phenylacetate Inhibit the Induction of Nitric Oxide Synthase and Cytokines in Rat Primary Astrocytes, Microglia, and Macrophages. *J.Clin. Invest.* Vol.100, #11, 2671-2679 (Dec.1997).

CEREBRAL ISCHEMIC INJURY

- Qi X., Hosoi T., Okuma Y., Kaneko M., Nomura Y., Sodium 4-Phenylbutyrate Protects against Cerebral Ischemic Injury, *Molecular Pharmacology* 66:899-908, 2004.

EPILEPSY

- Bogdanovic, M.D., Kidd, D., Bridson, A., Duncan, J.S., Land, M.M. Late onset heterozygous ornithine transcarbamylase deficiency mimicking complex partial status epilepticus. *J. Neurol. Neurosurg Psychiatry*, 2000,;69:813-815

CARDIAC INJURY

Daosukho,C., Chen, Y., Noel, T., Sompol, P., Nithipongvanitch, R., Velex, J.M., Oberley, T.D., St. Clair, D.K. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. *Free Rauduc Bio Med.* 42(12):1818-1825 June 15, 2007.

HUNTINGTON'S DISEASE

Hogarth, P, Lovrecic, L, Kraine, D. Sodium Phenylbutyrate in Huntington's Disease: A Dose-Finding Study. *Movement Disorders*, 2007, Vol. 22, No. 13.

Sadri-Vakili, Ghazaleh and Cha, Jang-Ho J. Mechanisms of Disease: histone modifications in Huntington's disease. *Nature Clinical Practice Neurology*, June 2006, Vol. 2, No. 6.

Borovecki F., Lovrecic L. Zhou J., Jeong H., Then F., Rosas H.D., Hersch S.M., Hogarth P., Bouzou B., Jensen R.V., Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. *PNAS* August 2, 2005, Vol. 102 No. 31 (11023-11028).

Gardian G., Browne S.E., Choi D-K., Klivenyi P., Gregorio J., Kubilus J.K., Ryus H., Langley B., Ratan R.R., Ferrante R.J., Beal M.F. Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. *The Journal of Biological Chemistry* Vol. 280, No.1, Jan. 7, 2005 (556-563).

Tolchin, E. Biomarkers of Huntington's Disease Found in Blood 7/26/05. *Bioscience Technology*, <http://www.biomedicalproducts.com>

Ferrante R.J., Kubilus J.K., Lee J., Ryu HI, Beesen A., Zucker B., Smith K., Kowall N. W., Ratan R. R., Luthi-Carter R., Hersch S.M., Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice. *J Neurosci* 2003; 23 (28): 9418-9427.

MULTIPLE SCLEROSIS (MS)

Dasgupta S, Zhou Y, Jana M, Banik NL, Pahan K. Sodium Phenylacetate Inhibits Adoptive Transfer of Experimental Allergic Encephalomyelitis in SJL/J Mice at Multiple Steps. *J Immunology* 2003, 170:3874-3882.

PARKINSON'S DISEASE

Kubota, Kyoko, Niinuma, Yoshifumi, Kaneko, Masayuki, Okuma, Yasunobu, Sugai, Mami, Omura, Tomohiro, Uesugi, Mai, Uehara, Takashi, Hosoi, Toru, Nomura, Yasuyuki. Suppressiv d effects of

4-Phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. *Journal of Neurochemistry*, 2006, 97, 1259-1268

Gardian, G., Yang, L., Cleren, C., Calingasan, N.Y., Klivenyi, P., and Beal, N.F. Neuroprotective Effects of Phenylbutyrate Against MPTP Neurotoxicity. *NeuroMolecule Medicine*, 2005 Volume 5

SPINAL MUSCULAR ATROPHY

Hauke, J, Riessland, M, Lunke, S, Eyoupoglu, IY, Bloumche, I, El-Osta, A, Wirth, B, Hahnen E. Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. *Hum Mol Genet* 2009 ; 18 (2) : 304-317.

Bosboom, WM, Vrancken, AF, van den Berg, LH, Wokke, JH, Iannaccone, ST. Drug treatment for spinal muscular atrophy types II and III. *Cochrane Database Syst Rev* 2009 ; 1 : CD006282.

Dayangaoc-Erden, D, TopaloAlu, H, Erdem-Yurter, H. A preliminary report on spinal muscular atrophy lymphoblastoid cells lines : are they an appropriate tool for drug screening ? *Adv Ther* 2008 ; 25 (3) : 274-279.

Dayangaç-Erden, Topaloğlu, Haluk, Erdem-Yurter, Hayat, A Preliminary Report on Spinal Muscular Atrophy Lymphoblastoid Cell Lines : Are They an Appropriate Tool for Drug Screening ? *Adv Ther* 2008 ;25(3) :274-279.

Mercuri, E., Bertini E., Messina S., Solari, A. etal. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. *Neurology* 2007;68:1-1

Darras, BT, Kang, PB. Clinical trials in spinal muscular atrophy. *Curr Opin Pediatr* 2007; 19 (6): 675-679.

Swoboda, KJ. Prospective evaluation of pre-symptomatic infants with spinal muscular atrophy: Implications for early therapeutic intervention. *Annals of Neurology* 2007; 62 (Suppl. 11): S2.

Davies S.L., Moral M.A. Spinal muscular atrophies – distinctions and therapeutic progress. *Drugs of the Future* 2006, 31(4):365-371.

Wirth, B, Brichta, L, Schrank, B, Lochmouller, H, Blick, S, Baasner, A, Heller, R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. *Hum Genet* 2006; 119 (4): 422-428

Wirth, B, Brichta, L, Hahnen, E. Spinal muscular atrophy: from gene to therapy. *Semin Pediatr Neurol* 2006; 13 (2): 121-131.

Wirth, B, Brichta, L, Hahnen, E. Spinal muscular atrophy and therapeutic prospects. *Prog Mol Subcell Biol* 2006; 44: 109-132.

Ganta M, Grzeschik SM, Heavlin WD, Wang CH. Phenylbutyrate modulates multiple neuronal survival gene expression in SMA cells. *Annals of Neurology* 2006; 60 (Suppl. 10): S140.

Brahe C., Vitali T., Tiziano F.D., Amgelozzi C., Pinto A.M., Borgo F., Moscato U., Bertini E., Mercuri E., Neri G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. *European J. of Human Genetics* (2005) 13, 256-259.

Schwartz, M. The molecular-genetic background of spinal muscular atrophy: Diagnosis, prognosis and future treatments. *Ugeskr Laeg* 2005: 167 (7): 745-748.

Mercuri E., Bertini E., Messina S., Pelliccioni M., D'Amico A., Colitto F., Mirabella M., Tiziano F.D., Vitali T., Angelozzi C., Kinali M., Main M., Brahe C. Pilot trial of phenylbutyrate in spinal muscular atrophy. *Neuromuscular Disorders* Vol 14, Issue 2,(130-135) Feb 2004.

Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Nmeri G., Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. *European Journal of Human Genetics* (2004) 12, 59-65

ALZHEIMER'S DISEASE

Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., García-Osta, A. Phenylbutyrate Ameliorates Cognitive Deficit and Reduces Tau Pathology in an Alzheimer's Disease Mouse Model. *Neuropsychopharmacology* January 14, 2009;doi:10.1038/nnp.2008.229

AGING

Wagner, G. Towards a life prolonging pill? Small molecules with anti-ageing properties. *Current Drug Targets* 2006: 7 (11): 1531-1537

Burzynski, S.R. Aging:gene silencing or gene activation? *Med Hypotheses* 2005: 64 (1): 201-208

Kang H-L., Benzer S., Min K-T. Life extension in *Drosophila* by feeding a drug. *PNAS* Jan 22, 2002, Vol. 99 No. 2, (838-843).

EYE

Gong Bo, Zhang Li-Yun, Lam Dennis Shun-Chiu, Pang Chi-Pui, Yam Gary Hin-Fai. Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells. *Molecular Vision* 2010 Kune 4, 2010

Yung-Yue Jeng, Nien-Ting Lin, Pen-Heng Chang, Yuan-Ping Huang, Victor Fei Pang, Chen-Hsuan Liu, Chung-Tien Lin. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. *Experimental Eye Research* (84 (2007) 486-492.

Gary Hin-Fai Yam, Katarina Gaplovska-Kysela, Christian Zuber, Jürgen Roth. Sodium 4-Phenylbutyrate Acts as a Chemical Chaperone on Misfolded Myocilin to Rescue Cells from Endoplasmic Reticulum Stress and Apoptosis. *Investigative Ophthalmology & Visual Science*, April 2007, Vol. 48, No.4.

Roth J, Yam GH-F, Gaplovska-Kysela K, Zuber C. Russell body formation and apoptosis in myocilin-caused primary open-angle glaucoma; rescue by the chemical chaperone sodium 4-phenylbutyrate. *FASEB Journal* 2007; 21 (5): A182.

Jeng Y-Y, Lin N-T, Chang P-H, Huang Y-P, Pang VF, Liu C-H, Lin C-T. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. *Exp Eye Res* 2007; 84 (3): 486-492.

RHEUMATOID ARTHRITIS

Yih-Lin Chung, Ming-Yuan Lee, Ae-June Wang, Lin-Fen Yao. A Therapeutic Strategy Uses Histone Deacetylase Inhibitors to Modulate the Expression of Genes Involved in the Pathogenesis of Rheumatoid Arthritis. *Molecular Therapy* Vol. 8, No. 5, November 2003

DIABETES

Brend Ray-Sea Hsu, Sxu-Tan Chen, Shin-Huei Fu. Enhancing engraftment of islets using perioperative sodium 4-phenylbutyrate. *International Immunopharmacology* 6 (206) 1952-1959

Fu S.H., Chen S.T., Hsu B.R.S, Attenuation of Primary Nonfunction for Syngeneic Islet Graft Using Sodium 4-Phenylbutyrate. *Transplantation Proceedings*, 37, 1830-1831 (2005).

A-1 ANTITRYPSIN

Burrows J.A., Willis L.K., Perlmutter D.H. Chemical Chaperones Mediate Increased Secretion of Mutant α 1-antitrypsin (α 1-AT) Z: A Potential Pharmacological Strategy for Prevention of Liver Injury and Emphysema in α 1-AT Deficiency. *PNAS*, 97(4):1796-1801. Feb 2000.

LIVER

Hayashi, Hisamitsu and Sugiyama, Yuichi. 4-Phenylbutyrate Enhances the Cell Surface Expression and the Transport Capacity of Wild-Type and Mutated Bile Salt Export Pumps. *Hepatology* 2007. 45:1506-1516.

Vilatoba M., Eckstein C., Bilbao G., Smyth C.A., Jenkins S. Thompson J.A., Eckhoff D.E., Contreras J.L. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. *Surgery* Aug 2005; 138:342-51.

ADDICTION

Romieu P, Host L, Gobaille S, Sandner G, Aunis D, Zwiller J. Histone deacetylase inhibitors decrease cocaine but not sucrose self-administration in rats. *J Neurosci* 2008; 28 (38): 9342-9348

ENDOPLASMIC RETICULUM STRESS

Choi SW, Ryu OH, Choi SJ, Song IS, Bleyer AJ, Hart TC. Mutant tamm-horsfall glycoprotein accumulation in endoplasmic reticulum induces apoptosis reversed by colchicines and sodium 4-phenylbutyrate. *J Am Soc Nephrol* 2005; 16 (10): 3006-3014.

Kubota K, Niinuma Y, Kaneko M, Okuma Y, Sugai M, Omura T, Uesugi M, Uehara T, Hosoi T, Nomura Y. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. *J Neurochem* 2006; 97 (5): 1259-1268.

Yam GF-F, Gaplovska-Kysela K, Zuber C, Roth J. Sodium 4-phenylbutyrate acts as a chemical chaperone on misfolded myocilin to rescue cells from endoplasmic reticulum stress and apoptosis. *J Invest Ophthalmol Vis Sci* 2007; 48 (4): 1683-1690.

Jang H-J, Jung J, Ha E-S, Choi S-E, Jung S, Kim H, Kim F, Kang Y, Lee K-W. 4PBA (4-phenylbutyrate) reduced palmitate-induced endoplasmic reticulum stress and apoptosis in HUVEC. *Diabetologia* 2007; 50 (1): S278.

OBESITY

Basseri Sana, Lhotak Sarka, Sharma Arya M, Austin Richard C. The chemical chaperone 4-phenylbutyrate inhibits adipogenesis by modulating the unfolded protein response. *Journal of Lipid Research* May 2009

MISCELLANEOUS RESEARCH & ARTICLES

Rougé, C, Des Robert, C, Robins, A, Le Bacquer, O, Volteau, C, DeLaCocheitière, M-F, Darmaun, D. Manipulation of Citrulline Availability in Humans. *Am J Physiol Gastrointest Liver Physiol* 293: G1061-G1067, 2007.

Caruthers R.L., Johnson C.E. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. *Am J Health-Syst Pharm* – Vol 64, July 15, 2007.

- Caruthers RL. Stability of sodium phenylbutyrate in two oral liquid vehicles. *ASHP Midyear Clinical Meeting*. 2006; 41.
- Kasumov T., Brunengraber L.L., Comte B., Puchowicz M., Jobbins K., Thomas K, David F., Kinman R., Wehrli S., Dahms W., Kerr D., Nissim I., Brunengraber H. New Secondary Metabolites of Phenylbutyrate in Humans and Rats. *Drug Metabolism and Disposition* Vol. 32, No. 1 32:10-19, 2004.
- Hommes FA. The assay of phenylacetic acid and 4-phenylbutyric acid in physiological fluids. *Clinica Chimica Acta*, 284: 109-111. 1999.
- McCall N., Samid D., Figg W. Stability of Phenylacetate and Phenylbutyrate in Parenteral Large-volume Sterile Water. *Drug Stability*, 1:54-58. 1995.
- Thibault A., Figg W., McCall N., Samid S., Myers C., Cooper M. A Simultaneous Assay of the Differentiation Agents Phenylacetic Acid and Phenylbutyric Acid, and one of their Metabolites, Phenylacetylglutamine, by Reversed-phase, High Performance Liquid Chromatography. *J. Liq. Chrom.*, 17:2895-1900. 1994.
- G.A. Ballou, P.D. Boyer, J.M. Luck, F.G. Lum, Chemical, Clinical, and Immunological Studies on the Products of Human Plasma Fractionation. V. The Influence of non-polar anions on the thermal stability of serum albumin. *Biochemical Laboratory, Department of Chemistry, Stanford University, California* Feb. 17, 1944

DISCLAIMER: The information presented is intended for educational purposes for health professionals and practitioners, and is obtained from published research. It is not intended to be prescriptive nor to replace the care of a licensed health professional in the diagnosis and treatment of illness.



Scandinavian Formulas

140 East Church Street, Sellersville PA 18960 USA

Tel: 215-453-2507 Fax: 215-257-9781

www.spb11.com info@spb11.com